scholarly journals Application of Metabolomics to Identify Potential Biomarkers for the Early Diagnosis of Coronary Heart Disease

2021 ◽  
Vol 12 ◽  
Author(s):  
Huali Jiang ◽  
Li Li ◽  
Weijie Chen ◽  
Benfa Chen ◽  
Heng Li ◽  
...  
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Early Diagnosis ◽  
Serum Samples ◽  
Clinical Model ◽  
Model Combining ◽  
Causes Of Deaths ◽  
Metabolic Biomarkers ◽  
Serum Metabolomics ◽  
Potential Biomarkers

Coronary heart disease (CHD) is one of the leading causes of deaths globally. Identification of serum metabolic biomarkers for its early diagnosis is thus much desirable. Serum samples were collected from healthy controls (n = 86) and patients with CHD (n = 166) and subjected to untargeted and targeted metabolomics analyses. Subsequently, potential biomarkers were detected and screened, and a clinical model was developed for diagnosing CHD. Four dysregulated metabolites, namely PC(17:0/0:0), oxyneurine, acetylcarnitine, and isoundecylic acid, were identified. Isoundecylic acid was not found in Human Metabolome Database, so we could not validate differences in its relative abundance levels. Further, the clinical model combining serum oxyneurine, triglyceride, and weight was found to be more robust than that based on PC(17:0/0:0), oxyneurine, and acetylcarnitine (AUC = 0.731 vs. 0.579, sensitivity = 83.0 vs. 75.5%, and specificity = 64.0 vs. 46.5%). Our findings indicated that serum metabolomics is an effective method to identify differential metabolites and that serum oxyneurine, triglyceride, and weight appear to be promising biomarkers for the early diagnosis of CHD.

scholarly journals A Metabonomics Profiling Study on Phlegm Syndrome and Blood-Stasis Syndrome in Coronary Heart Disease Patients Using Liquid Chromatography/Quadrupole Time-of-Flight Mass Spectrometry

2014 ◽  
Vol 2014 ◽  
pp. 1-10 ◽  
Author(s):  
Linlin Zhao ◽  
Ling Wan ◽  
Xinjian Qiu ◽  
Ruomeng Li ◽  
Shimi Liu ◽  
...  
Keyword(s):  
Mass Spectrometry ◽  
Coronary Heart Disease ◽  
Heart Disease ◽  
Liquid Chromatography ◽  
Acid Metabolism ◽  
Blood Stasis ◽  
Blood Stasis Syndrome ◽  
Flight Mass Spectrometry ◽  
Potential Biomarkers ◽  
Phlegm Syndrome

A metabonomics approach based on liquid chromatography/quadrupole time-of-flight mass spectrometry (LC-Q-TOF/MS) was utilized to obtain potential biomarkers of coronary heart disease (CHD) patients and investigate the ZHENG types differentiation in CHD patients. The plasma samples of 20 CHD patients with phlegm syndrome, 20 CHD patients with blood-stasis syndrome, and 16 healthy volunteers were collected in the study. 26 potential biomarkers were identified in the plasma of CHD patients and 19 differential metabolites contributed to the discrimination of phlegm syndrome and blood-stasis syndrome in CHD patients(VIP>1.5; P<0.05)which mainly involved purine metabolism, pyrimidine metabolism, amino acid metabolism, steroid biosynthesis, and arachidonic acid metabolism. This study demonstrated that metabonomics approach based on LC-MS was useful for studying pathologic changes of CHD patients and interpreting the differentiation of ZHENG types (phlegm and blood-stasis syndrome) in traditional Chinese medicine (TCM).

scholarly journals Serum Metabolomic Analysis of Coronary Heart Disease Patients with Stable Angina Pectoris Subtyped by Traditional Chinese Medicine Diagnostics Reveals Biomarkers Relevant to Personalized Treatments

2021 ◽  
Vol 12 ◽  
Author(s):  
Na Guo ◽  
Peili Wang ◽  
Jiaying Yang ◽  
Xiaofang Yang ◽  
Monique van der Voet ◽  
...  
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Chinese Medicine ◽  
Angina Pectoris ◽  
Traditional Chinese Medicine ◽  
Bile Acid Metabolism ◽  
Targeted Metabolomics ◽  
Unsaturated Lipids ◽  
Long Chain ◽  
Potential Biomarkers

To improve the treatment of patients with coronary heart disease (CHD), personalized treatments based on potential biomarkers could make a difference. To investigate if such potential biomarkers could be found for CHD inhomogeneous, we combined traditional Chinese medicine based diagnosis with untargeted and targeted metabolomics analyses. Shi and Xu patient subtype groups of CHD with angina pectoris were identified. Different metabolites including lipids, fatty acids and amino acids were further analyzed with targeted metabolomics and mapped to disease-related pathways. The long-chain unsaturated lipids ceramides metabolism, bile acid metabolism were differentially affected in the Xu subtype groups. While, Shi-subtype patients seemed to show inflammation, anomalous levels of bioactive phospholipids and antioxidant molecules. Furthermore, variations in the endothelial damage response and energy metabolism found based on ELISA analysis are the key divergence points between different CHD subtypes. The results showed Xu subtype patients might benefit from long-chain unsaturated lipids ceramides as therapeutic targets. Shi subtype patients might benefit more from levels of polyunsaturated fatty acid consumption and treatments that help in restoring energy balance. Metabolic differences can be essential for treatment protocols. Thus, patient group specific differences can serve as important information to refine current treatment approaches in a personalized manner.

scholarly journals Exploring potential biomarkers of coronary heart disease treated by Jing Zhi Guan Xin Pian using high-throughput metabolomics

RSC Advances ◽  
2019 ◽  
Vol 9 (20) ◽  
pp. 11420-11432 ◽  
Author(s):  
Hui Sun ◽  
Xue-na Li ◽  
Ai-hua Zhang ◽  
Kun-ming Zhang ◽  
Guang-li Yan ◽  
...  
Keyword(s):  
Coronary Heart Disease ◽  
Blood Flow ◽  
Heart Disease ◽  
High Throughput ◽  
Complex Disease ◽  
Arterial Lumen ◽  
Potential Biomarkers

Coronary heart disease (CHD) is a relatively complex disease characterized by narrowing of the arterial lumen and reduction of blood flow to the heart.

An Acridinium Ester for Determination of Serum Arylesterase Activity in Patients with Coronary Heart Disease

2013 ◽  
Vol 781-784 ◽  
pp. 812-817
Author(s):  
Yu Hua Gong ◽  
Xiao Jing Mu ◽  
Zhi Tao Chen ◽  
Zulipiyan Abulimite ◽  
Min Liu ◽  
...  
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Chronic Diseases ◽  
Negative Correlation ◽  
Phenyl Acetate ◽  
Serum Samples ◽  
Significant Difference ◽  
Acridinium Ester

Paraoxonase (PON) is a hydrolyase correlated with many chronic diseases. The use of 9-(4-chlorophenyloxycarbonyl)-10-methylacridinium triflate ester (CPOCMA) as a substrate for determination of serum arylesterase PON activity had been reported. It is meaningful to compare this substrate with phenyl acetate further with serum samples of patients with coronary heart disease (CHD, n=104). Correlations of PON arylesterase activity with CHD and also with age were analyzed. There was no significant difference in serum arylesterase activity (based on the CPOCMA or the phenyl acetate) between of the CHD inpatients and controls at same age level (45-60 years old). Statistically negative correlation of serum PON CPOCMAase activity (p=0.020) but not the activity based on phenyl acetate (p>0.05) with age was observed. Based on the both substrates, significant decrease in PON activity was found in the old CHD inpatients (≥60 years old), compared with that in the young CHD inpatients (<60 years old), or with that in the young controls. The methods based on CPOCMA substrate and based on the phenyl acetate demonstrated consistent results in correlation with CHD, but different results in correlation of PON activity with age.

scholarly journals The Serum Analysis of Dampness Syndrome in Patients with Coronary Heart Disease and Chronic Renal Failure Based on the Theory of “Same Syndromes in Different Diseases”

2017 ◽  
Vol 2017 ◽  
pp. 1-10 ◽  
Author(s):  
Yiming Hao ◽  
Xue Yuan ◽  
Peng Qian ◽  
Guanfeng Bai ◽  
Yiqin Wang
Keyword(s):  
Coronary Heart Disease ◽  
Renal Failure ◽  
Heart Disease ◽  
Chronic Renal Failure ◽  
Healthy Subjects ◽  
Principal Component ◽  
Serum Samples ◽  
Serum Metabolites ◽  
Underlying Basis ◽  
Patient Groups

Aim. To analyze the serum metabolites in patients with coronary heart disease (CHD) showing dampness syndrome and patients with chronic renal failure (CRF) showing dampness syndrome and to seek the substance that serves as the underlying basis of dampness syndrome in “same syndromes in different diseases.” Methods. Metabolic spectrum by GC-MS was performed using serum samples from 29 patients with CHD showing dampness syndrome and 32 patients with CRF showing dampness syndrome. The principal component analysis and statistical analysis of partial least squares were performed to detect the metabolites with different levels of expression in patients with CHD and CRF. Furthermore, by comparing the VIP value and data mining in METLIN and HMDB, we identified the common metabolites in both patient groups. Results. (1) Ten differential metabolites were found in patients with CHD showing dampness syndrome when compared to healthy subjects. Meanwhile, nine differential metabolites were found in patients with CRF showing dampness syndrome when compared to healthy subjects. (2) There were 9 differential metabolites identified when the serum metabolites of the CHD patients with dampness syndrome were compared to those of CRF patients with dampness syndrome. There were 4 common metabolites found in the serums of both patient groups.

Sign in / Sign up

Export Citation Format

Share Document